Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma;   Hematopoietic Cell Transplantation Recipient;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/My eloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Waldens trom Macroglobulinemia;   T-Cell Chronic Lymphocytic Leukemia Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI) Not yet recruiting - verified August 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials